Gut microbiome profile in psoriatic patients treated and untreated with biologic therapy.
Akkermansia muciniphila
16S rRNA sequencing
biologic therapy
gut microbiome
psoriasis
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
05
2020
accepted:
09
10
2020
pubmed:
30
1
2021
medline:
3
6
2021
entrez:
29
1
2021
Statut:
ppublish
Résumé
There are increasing data about the role of the gut microbiome in various autoimmune diseases, including psoriasis, a chronic inflammatory and immune-mediated disease. Current treatment strategies in psoriasis include immunomodulating biologic agents. A variable response to this type of therapy has been reported in psoriatic patients. A possible effect of biologic therapy on the gut microbiome composition has been suggested, but data are still limited. The aim of this study was to compare the gut microbiome composition between psoriatic patients treated and untreated with biologic drugs in order to identify differences which may highlight the potential impact of the treatment on the gut microbiome. 16S rRNA sequencing and bioinformatic analyses were performed on the fecal samples of 30 psoriatic patients with similar clinicopathological features, 10 of whom were undergoing biologic therapy and 20 not receiving systemic therapy. Alpha and beta diversity significantly differed between the two groups of patients. A reduced bacterial biodiversity in the group of treated patients compared with the group of untreated patients was observed. Differential relative abundances of key gut microbial communities, including Akkermansia muciniphila and Bacteroides plebeius, were identified between the two groups of patients. This study showed that biologic therapy may have an impact on the composition of the gut microbiome of psoriatic patients. Gut microbiome composition could be used as an indicator of response to therapy and the modulation of the microbial composition could help to restore the intestinal symbiosis in psoriatic patients.
Identifiants
pubmed: 33511673
doi: 10.1111/1346-8138.15680
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-793Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG21389
Informations de copyright
© 2021 Japanese Dermatological Association.
Références
Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417(6888): 552-555.
Stokes JH, Pillsbury DM. The effect on the skin of emotional and nervous states: I II. Theoretical and practical consideration of a gastro-intestinal mechanism. Arch Derm Syphilol 1930; 22: 962-993.
Cani PD. Gut microbiome and obesity: lessons from the microbiome. Brief Funct Genomics 2013; 12(4): 381-387.
Sommer F, Backhed F. The gut microbiome-masters of host development and physiology. Nat Rev Microbiol 2013; 11(4): 227-238.
Planer JD, Peng Y, Kau AL et al. Development of the gut microbiome and mucosal IgA responses in twins and gnotobiotic mice. Nature 2016; 534(7606): 263-236.
Benhadou F, Mintoff D, Schnebert B, Thio HB. Psoriasis and microbiome: a systematic review. Diseases 2018; 6(2): E47.
Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep 2013; 15(3): 314.
de Groot PF, Belzer C, Aydin O et al. Distinct fecal and oral microbiome composition in human type 1 diabetes, an observational study. PLoS One 2017; 12(12): e0188475.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis 2016; 22: 1137-1150.
Crow JM. Psoriasis uncovered. Nature 2012; 492(7429): S50-S51.
Griffiths CEM, van der Walt JM, Ashcroft DM et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol 2017; 177(1): e4-e7.
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci 2019; 20(18): E4347.
Richetta AG, Silvestri V, Giancristoforo S et al. A-1012G promoter polymorphism of vitamin D receptor gene is associated with psoriasis risk and lower allele-specific expression. DNA Cell Biol 2014; 33(2): 102-109.
Yan D, Issa N, Afifi L, Jeon C, Chang HW, Liao W. The role of the skin and gut microbiome in psoriatic disease. Curr Dermatol Rep 2017; 6: 94-103.
Thio HB. The microbiome in psoriasis and psoriatic arthritis: the skin perspective. J Rheumatol Suppl 2018; 94: 30-31.
Wang WM, Jin HZ. Skin microbiome: an actor in the pathogenesis of psoriasis. Chin Med J (Engl) 2018; 131(1): 95-98.
Alesa DI, Alshamrani HM, Alzahrani YA, Alamssi DN, Alzahrani NS, Almohammadi ME. The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. J Family Med Prim Care 2019; 8(11): 3496-3503.
Hidalgo-Cantabrana C, Gómez J, Delgado S et al. Gut microbiome dysbiosis in a cohort of patients with psoriasis. Br J Dermatol 2019; 181(6): 1287-1295.
Visser MJE, Kell DB, Pretorius E. Bacterial dysbiosis and translocation in psoriasis vulgaris. Front Cell Infect Microbiol. 2019; 9: 7.
Valdimarsson H, Baker BS, Jónsdóttir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 176: 7104-7111.
Mattozzi C, Richetta AG, Cantisani C, Macaluso L, Calvieri S. Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR/CATERPILLER family genes and microbial flora. J Dermatol 2012; 39: 752-760.
Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W. Diet and psoriasis, part II: celiac disease and role of a gluten-free diet. J Am Acad Dermatol 2014; 71: 350-358.
Potenza MC, Peris K, Berardesca E et al. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: results from the PSONG survey. Dermatol Ther 2018; 31(1): e12565.
Kostaki D, Aquila E, Macaluso L, Mattozzi C, Richetta AG. Optimizing secukinumab treatment in psoriasis with concomitant methotrexate administration: minireview and a case report. Case Rep Dermatol 2019; 11(Suppl 1): 17-22.
Martin R, Henley JB, Sarrazin P, Seité S. Skin microbiome in patients with psoriasis before and after balneotherapy at the thermal care center of La Roche-Posay. J Drugs Dermatol 2015; 14: 1400-1405.
Assarsson M, Duvetorp A, Dienus O, Söderman J, Seifert O. Significant changes in the skin microbiome in patients with chronic plaque psoriasis after treatment with narrowband ultraviolet B. Acta Derm Venereol 2018; 98: 428-436.
Loesche MA, Farahi K, Capone K et al. Longitudinal study of the psoriasis associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. J Invest Dermatol 2018; 138: 1973-1981.
Yeh NL, Hsu CY, Tsai TF, Chiu HY. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin Drug Investig 2019; 39(12): 1195-1203.
Klindworth A, Pruesse E, Schweer T et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 2013; 41(1): e1.
Bokulich NA, Dillon MR, Zhang Y et al. q2-longitudinal: Longitudinal and Paired-Sample Analyses of Microbiome Data. mSystems 2018; 3(6): e00219-18.
Bokulich NA, Kaehler BD, Rideout JR et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-featureclassifier plugin. Microbiome 2018; 6(1): 90.
Lydon KA, Lipp EK. Taxonomic annotation errors incorrectly assign the family Pseudoalteromonadaceae to the order Vibrionales in Greengenes: implications for microbial community assessments. PeerJ 2018; 6: e5248.
Huang L, Gao R, Yu N, Zhu Y, Ding Y, Qin H. Dysbiosis of gut microbiota was closely associated with psoriasis. Sci China Life Sci 2019; 62(6): 807-815.
Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O, Maharshak N. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol 2019; 46(7): 595-603.
Scher JU, Ubeda C, Artacho A et al. Decreased bacterial diversity characterizes the altered gut microbiome in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015; 67(1): 128-139.
Codoñer FM, Ramírez-Bosca A, Climent E et al. Gut microbial composition in patients with psoriasis. Sci Rep 2018; 8(1): 3812.
Masallat D, Moemen D, State AF. Gut bacterial microbiota in psoriasis: a case control study. Afr J Microbiol Res 2016; 10(33): 1337-1343.
O'Neill CA, Monteleone G, McLaughlin JT, Paus R. The gut-skin axis in health and disease: a paradigm with therapeutic implications. BioEssays 2016; 38(11): 1167-1176.
Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-625.
Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O'Connell PR. Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum 2010; 53(11): 1530-1536.
Sawin EA, De Wolfe TJ, Aktas B et al. Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice. Am J Physiol Gastrointest Liver Physiol 2015; 309(7): G590-G601.
Hynönen U, Rasinkangas P, Satokari R et al. Isolation and whole genome sequencing of a Ruminococcus-like bacterium, associated with irritable bowel syndrome. Anaerobe 2016; 39: 60-67.
Wu X, He B, Liu J et al. Molecular insight into gut microbiome and rheumatoid arthritis. Int J Mol Sci 2016; 17(3): 431.
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27(2): 104-119.
Yu R, Zuo F, Ma H, Chen S. Exopolysaccharide-producing bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 Axis of DSS-Colitis Mice. Nutrients 2019; 11(4): 782.
Gómez-Gallego C, Pohl S, Salminen S, De Vos WM, Kneifel W. Akkermansia muciniphila: a novel functional microbe with probiotic properties. Benef Microbes 2016; 7(4): 571-584.
Ottman N, Huuskonen L, Reunanen J et al. Characterization of Outer Membrane Proteome of Akkermansia muciniphila Reveals Sets of Novel Proteins Exposed to the Human Intestine. Front Microbiol 2016; 7: 1157.
Schneeberger MA, Everard AG, Gomez-Valades S et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep 2015; 5: 16643.
Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog 2017; 106: 171-181.
Dao MC, Everard A, Aron-Wisnewsky J et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 2016; 65(3): 426-436.
Tan L, Zhao S, Zhu W et al. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol 2018; 27(2): 144-149.
Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatolog Ther 2010; 1: S14-S19.